The content on this site is intended for healthcare professionals only
Dr Elizabeth Pease speaks to ecancer at the WIN 2019 Symposium in Paris about the use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies.
She explains that by combining drugs the hope is that responses are deeper and more durable.
Dr Pease explains that developing these combinations is tricky and that it is important to look into the dosing, schedule and application to the right patient populations in order to maximise the benefit.
Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Revolutionising myeloma treatment through immune profiling
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Durable responses in aRCC, how do we optimise treatment?
